Literature DB >> 22811825

Prevalence of adenocarcinoma at esophagectomy for Barrett's esophagus with high grade dysplasia.

John Y Nasr1, Robert E Schoen.   

Abstract

BACKGROUND: Barrett's esophagus with high grade dysplasia (HGD) may require surgical resection because of the risk of concomitant adenocarcinoma. The prevalence of invasive, occult carcinoma (≥stage 1B) in this setting has varied. We investigated the association of adenocarcinoma at operative resection for high grade dysplasia.
METHODS: Using an electronic medical record, we identified patients who underwent esophagectomy for high grade dysplasia at the University of Pittsburgh Medical Center between 1993 and 2007. Preoperative diagnosis was confirmed by reviewing endoscopic, radiologic and pathology reports. Postoperative pathology reports were compared to the preoperative diagnosis.
RESULTS: 68 patients (12 females and 56 males) with a preoperative diagnosis of high grade dysplasia underwent operative resection. The mean age was 64 years (range 36 to 86 years). Of 68 patients, 12 (17.6%) had adenocarcinoma, 2 (2.9%) were downgraded to low grade dysplasia, and 54 (79.4%) were confirmed as HGD. Of the 12 patients with adenocarcinoma, 4 (5.9% of total cohort) had intramucosal cancer (Stage 1A) and 8 (11.7% of total cohort) had invasive cancer with submucosal invasion or more advanced disease. Of the 8 patients with invasive adenocarcinoma, 4 did not have preoperative endoscopic or radiologic testing suggestive of advanced disease.
CONCLUSION: The overall prevalence of adenocarcinoma in association with a preoperative diagnosis of HGD was 17.6%. Invasive adenocarcinoma was present in 11.7% of subjects and was clinically occult in 5.9%.

Entities:  

Keywords:  Barrett’s; adenocarcinoma of esophagus; esophagectomy; high grade dysplasia

Year:  2011        PMID: 22811825      PMCID: PMC3397590          DOI: 10.3978/j.issn.2078-6891.2010.027

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  18 in total

Review 1.  Photodynamic therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  Herbert C Wolfsen
Journal:  Compr Ther       Date:  2005

Review 2.  Pro: esophagectomy is the treatment of choice for high-grade dysplasia in Barrett's esophagus.

Authors:  Thomas W Rice
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

Review 3.  CON: surgery for Barrett's with flat HGD-no!

Authors:  Stephen J Sontag
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

4.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  M J Edwards; D R Gable; A B Lentsch; J D Richardson
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

5.  Surgical treatment of esophageal high-grade dysplasia.

Authors:  Michael F Reed; George Tolis; Barish H Edil; James S Allan; Dean M Donahue; Henning A Gaissert; Ashby C Moncure; John C Wain; Cameron D Wright; Douglas J Mathisen
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

6.  Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma.

Authors:  N S Buttar; K K Wang; T J Sebo; D M Riehle; K K Krishnadath; L S Lutzke; M A Anderson; T M Petterson; L J Burgart
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

7.  Impact of hospital volume on operative mortality for major cancer surgery.

Authors:  C B Begg; L D Cramer; W J Hoskins; M F Brennan
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

8.  Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?

Authors:  Vani J A Konda; Andrew S Ross; Mark K Ferguson; John A Hart; Shang Lin; Keith Naylor; Amy Noffsinger; Mitchell C Posner; Charles Dye; Barbara Cislo; Lynne Stearns; Irving Waxman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-12-21       Impact factor: 11.382

9.  Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.

Authors:  Bergein F Overholt; Kenneth K Wang; J Steven Burdick; Charles J Lightdale; Michael Kimmey; Hector R Nava; Michael V Sivak; Norman Nishioka; Hugh Barr; Norman Marcon; Marcos Pedrosa; Mary P Bronner; Michael Grace; Michelle Depot
Journal:  Gastrointest Endosc       Date:  2007-07-23       Impact factor: 9.427

10.  Laparoscopic transhiatal esophagectomy for Barrett's esophagus with high grade dysplasia.

Authors:  J D Luketich; N T Nguyen; P R Schauer
Journal:  JSLS       Date:  1998 Jan-Mar       Impact factor: 2.172

View more
  11 in total

1.  Low risk of prevalent submucosal invasive cancer among patients undergoing esophagectomy for treatment of Barrett's esophagus with high grade dysplasia.

Authors:  Vani Ja Konda; Irving Waxman
Journal:  J Gastrointest Oncol       Date:  2011-03

2.  Low prevalence of invasive adenocarcinoma and occult cancer on esophageal resection for Barrett's esophagus with high-grade dysplasia: Evidence for conservative management.

Authors:  Deepa T Patil; Thomas P Plesec; John R Goldblum
Journal:  J Gastrointest Oncol       Date:  2011-03

3.  Early enteral infusion of traditional Chinese medicine preparation can effectively promote the recovery of gastrointestinal function after esophageal cancer surgery.

Authors:  Yi Hu; Yun Ma; Jian Wang; Zhi-Hua Zhu
Journal:  J Thorac Dis       Date:  2011-12       Impact factor: 2.895

4.  Beclin 1 expression is associated with the occurrence and development of esophageal squamous cell carcinoma.

Authors:  Hailei Du; Jiamin Che; Minmin Shi; Lianggang Zhu; Jun Biao Hang; Zhongyuan Chen; Hecheng Li
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

Review 5.  Management controversies in Barrett's oesophagus.

Authors:  L Max Almond; Hugh Barr
Journal:  J Gastroenterol       Date:  2013-06-05       Impact factor: 7.527

Review 6.  Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all?

Authors:  Giovanni Zaninotto; Cathy Bennett
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

7.  Increased detection of Barrett's esophagus and esophageal dysplasia with adjunctive use of wide-area transepithelial sample with three-dimensional computer-assisted analysis (WATS).

Authors:  Seth A Gross; Michael S Smith; Vivek Kaul
Journal:  United European Gastroenterol J       Date:  2017-11-28       Impact factor: 4.623

8.  HtrA1 expression associated with the occurrence and development of esophageal cancer.

Authors:  Youtao Yu; Wenlong Shao; Yi Hu; Jingyan Zhang; Hao Song; Zhi-hua Zhu
Journal:  World J Surg Oncol       Date:  2012-08-30       Impact factor: 2.754

9.  Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry.

Authors:  R J Haidry; M A Butt; J M Dunn; A Gupta; G Lipman; H L Smart; P Bhandari; L Smith; R Willert; G Fullarton; M Di Pietro; C Gordon; I Penman; H Barr; P Patel; N Kapoor; J Hoare; R Narayanasamy; Y Ang; A Veitch; K Ragunath; M Novelli; L B Lovat
Journal:  Gut       Date:  2014-12-24       Impact factor: 23.059

10.  Diagnosis and Management of Barrett's Esophagus: A Retrospective Study Comparing the Endoscopic Assessment of Early Esophageal Lesions in the Community versus a Specialized Center.

Authors:  Erin Rayner-Hartley; Oliver Takach; Cherry Galorport; Robert A Enns
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.